title: Clinical implications of molecular heterogeneity in triple negative breast cancer.
abstract: Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials.
authors.affiliation: Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Preston Research Building, 2200 Pierce Avenue, Nashville, TN 37232, USA. Electronic address: brian.d.lehmann@vanderbilt.edu.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Lehmann
authors.affiliation: Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Preston Research Building, 2200 Pierce Avenue, Nashville, TN 37232, USA. Electronic address: j.pietenpol@vanderbilt.edu.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Pietenpol
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D018740:Genetic Heterogeneity; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D010641:Phenotype; D014158:Transcription, Genetic; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
keywords: Androgen receptor; Chemotherapy; Neoadjuvant; PIK3CA; TNBCtype